Tandem Diabetes Care, Inc. (TNDM) reported $247.22 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 5.5%. EPS of -$0.30 for the same period compares to -$0.67 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $238.95 million, representing a surprise of +3.46%. The company delivered an EPS surprise of +34.78%, with the consensus EPS estimate being -$0.46.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Tandem Diabetes Care performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Sales- United States: $160.84 million compared to the $153.15 million average estimate based on three analysts. The reported number represents a change of +6.8% year over year. Geographic Sales- Outside the United States: $86.38 million compared to the $85.43 million average estimate based on three analysts. The reported number represents a change of +3.1% year over year. Sales- Supplies and Other- Outside the United States: $53.89 million compared to the $54.54 million average estimate based on three analysts. The reported number represents a change of +0.1% year over year. Sales- Pump- Outside the United States: $32.49 million compared to the $30.9 million average estimate based on three analysts. The reported number represents a change of +8.5% year over year. Sales- Supplies and Other- United States: $82.9 million compared to the $84.47 million average estimate based on three analysts. The reported number represents a change of +5.6% year over year. Sales- Pump- United States: $77.94 million versus the three-analyst average estimate of $68.68 million. The reported number represents a year-over-year change of +8%. Revenue- Supplies and Other: $136.8 million versus the three-analyst average estimate of $139.01 million. The reported number represents a year-over-year change of +3.4%. Revenue- Pump: $110.43 million versus $99.57 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8.2% change.View all Key Company Metrics for Tandem Diabetes Care here>>>
Shares of Tandem Diabetes Care have returned -6.8% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).